Document is current

Article History

Accepted: 14 March 2022

First Online: 23 April 2022

Declarations

:

: This study was sponsored by Janssen. Medical writing and editorial support were funded by Janssen. Open access publication was funded by Janssen.

: LGR has been a speaker and advisory board member for Janssen-Cilag, Angelini, Casen-Recordati, Lundbeck, Otsuka, Novartis, GSK, and Pfizer. SSA has been a speaker and advisory board member for Janssen-Cilag, Angelini, Casen-Recordati, Lundbeck, Otsuka, Qualigen, and Adamed. MGD and PLR are full-time employees of Janssen.

: This study was conducted according to guidelines on observational post-authorization studies for medicinal products for human use specified in Orden SAS/3470/2009 of the Spanish Agency of Medicines and Medical Devices (AEMPS). The study was also conducted according to good clinical practice guidelines (International Conference for Harmonization) and the Declaration of Helsinki and was approved by a public hospital ethics committee in Spain.

: All identifiable personal information was removed for privacy protection prior to data acquisition, so the requirement for informed consent was waived.

: Not applicable.

: The data analyzed in this study are not publicly available according to the licensing agreement with IQVIA.

: Not applicable.

: MGD and PLR designed the study concept. LGR, SSA, MGD, and PLR participated in data analysis and interpretation and in the review and editing of the article. LGR and SSA wrote the first draft. All authors critically reviewed the manuscript. All authors provided input into the drafting of the manuscript, have read, and approved the final submitted version to be published, and agree to be accountable for the work as a whole.